Latest

Pharm Exec's Emerging Pharma Leaders 2018

Pharm Exec’s 11th annual list profiles the diverse stories of 10 rising biopharma managers—and how each are changing the ways leaders direct critical industry functions.

Choosing the Right Track: Pharma & Healthcare MBAs

A growing range of MBAs with concentrations in pharmaceuticals and healthcare management are on offer. Pharm Exec look at how three of the top programs in the US prepare their students for industry success.

Social Science Behavior Change Models: The Key to More Targeted Messages

Charles Daramola discusses the application of social science behavior change theories and models to physician sales.

Congressional Action Alters FDA Policies, Pharma Practices

Congress approves bills with provisions important to FDA and industry, some of which reflect continuing concerns about drug pricing and transparency.

Pharm Exec Video

Behind the Scenes with Kallyope’s Nancy Thornberry

A sneak peek at Pharm Exec's August cover shoot with the New York City-based biotech CEO.

Why One Korean Biotech Picked New Jersey for U.S. Headquarters

New Jersey is still a top pick for companies when it comes to pharma.

Pharm Exec Talks Partnerships with Sanofi

Hear what Sanofi looks for when they decide to form a partnership with another company.

New & Noteworthy

Four Challenges Preventing AI Reaching Its Full Potential

AI has become ubiquitous in all industries, including life sciences. But is also attracting some concerns – particularly around job losses, ethics, and more broadly, how successful it really is, writes Steve Arlington.

What the Age of Multi-Localism Means for Pharma

New realities are transforming the global environment and upending a business model based on the presumption of ever more connected markets. Paul A. Laudicina asks, What does this mean for pharma?

Managing Local Language Regulatory Submissions

Preparing products for distribution in international markets is far from straightforward. Nancy Pollini looks at what constitutes best practice in managing translations in today’s regulatory affairs environment.

Why Your Advertising Agency Should Be Your Analytics Partner

Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.

Sales & Marketing

Social Science Behavior Change Models: The Key to More Targeted Messages

Charles Daramola discusses the application of social science behavior change theories and models to physician sales.

Why Your Advertising Agency Should Be Your Analytics Partner

Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.

Learning, Retaining, Applying Information: Preparing Reps for Success in the Field

The most effective way to train sales reps and boost their success is to consider the learner/user experience in all facets, in every training encounter, and on each training platform, writes Shaun McMahon.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

Getting Where You Need to Go

As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.

Big Companies Driving FDA Fast Lanes

Use of FDA's options for speedier approval applied to more than half of novel drug approvals in recent years. But which drugs–and from which companies–are being approved faster? Leela Barham reports.

Crash Course in Strategy

New life sciences internship program has high-level mission. Michelle Maskaly reports.

Vienna’s Vision on Health Regulation in Europe

What will come out of Austria’s shakeup of European pharma rules? Reflector reports.

Interviews

The Path to Pioneership: Dr. J. Joseph Kim, Inovio Pharmaceuticals

Pharm Exec speaks to Inovio Pharmaceuticals' Dr. J. Joseph Kim about his journey from humble beginnings as an 11-year-old Korean immigrant to his present position at the forefront of a new medical frontier.

Paul Perreault: The Global CEO

Pharm Exec talks with CSL's top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.

Close to the Action: Dr. José Luis Cabero, CEO, AELIX Therapeutics

Pharm Exec talks to AELIX Therapeutics' Dr. José Luis Cabero about how the career and country shift he made a decade ago have motivated and sustained a new direction in his career.

Regulatory

Does Being an Orphan Speed Up FDA Approval?

Leela Barham looks at whether FDA approval is expedited when a drug not only secures one or more of the FDA’s expedited development and review methods, but is also when it is designated an orphan drug.

Big Companies Driving FDA Fast Lanes

Use of FDA's options for speedier approval applied to more than half of novel drug approvals in recent years. But which drugs–and from which companies–are being approved faster? Leela Barham reports.

Congressional Action Alters FDA Policies, Pharma Practices

Congress approves bills with provisions important to FDA and industry, some of which reflect continuing concerns about drug pricing and transparency.

Are the Right Drugs Getting Faster FDA Approval?

Leela Barham continues her series of features exploring expedited FDA approvals with a look at the therapy areas and the overlap with orphan drug designations.

From the Editor

Getting Where You Need to Go

As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.

Specialty Supply Chain Decisions

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

lorem ipsum